Clinical Trials on Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG in Canada
Total 15 results
-
Theralase® Technologies Inc.University Health Network, Toronto; Pharma eMarketRecruitingNon-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCGUnited States, Canada
-
Theralase Inc.University Health Network, Toronto; WCCT Global; Medelis Inc.CompletedNon-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCGCanada
-
CHU de Quebec-Universite LavalCanadian Institutes of Health Research (CIHR)RecruitingNon-Muscle Invasive Bladder CancerCanada
-
Astellas Pharma Global Development, Inc.Seagen Inc.RecruitingCarcinoma in Situ | Urinary Bladder Neoplasms | Non-muscle Invasive Bladder Cancer | Carcinoma Transitional Cell | NMIBCUnited States, Canada, France, Spain, United Kingdom, Germany
-
University of British ColumbiaWithdrawnBladder Cancer | High-Risk Cancer | Durvalumab | Non-muscle Invasive | TremelimumabCanada
-
AstraZenecaActive, not recruitingNon-muscle-invasive Bladder CancerFrance, Spain, Belgium, Canada, Poland, Germany, Japan, Russian Federation, United Kingdom, Austria, Australia, Netherlands
-
Mansoura UniversityRecruitingNon-Muscle Invasive Bladder CancerEgypt
-
Merck Sharp & Dohme LLCRecruitingHigh-risk Non-muscle Invasive Bladder CancerCanada, Belgium, United States, Australia, Austria, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Norway, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, China, Brazil, Co... and more
-
Merck Sharp & Dohme LLCRecruitingBladder CancerCanada, France, Italy, Netherlands, Turkey, Brazil, Spain, United States, Finland, Puerto Rico, Singapore
-
Sesen Bio, Inc.CompletedBladder CancerUnited States, Canada
-
PfizerActive, not recruitingNon-muscle Invasive Bladder CancerChina, United States, Spain, Belgium, Korea, Republic of, Australia, United Kingdom, Japan, France, Germany, Canada, Russian Federation, Poland, Italy
-
Janssen Research & Development, LLCRecruitingBladder CancerUnited States, Belgium, Korea, Republic of, Italy, Taiwan, China, United Kingdom, Germany, France, Argentina, Brazil, Poland, Spain, Czechia, Japan, Netherlands, India, Canada, Mexico, Australia, Portugal
-
Janssen Research & Development, LLCRecruitingUrinary Bladder NeoplasmsUnited States, Belgium, Korea, Republic of, Germany, Italy, France, Spain, Canada, United Kingdom, Greece, Japan, Netherlands, Portugal, Australia, Russian Federation, Ukraine
-
Bristol-Myers SquibbTerminatedUrinary Bladder NeoplasmsUnited States, Netherlands, Italy, Argentina, Australia, Austria, Brazil, Canada, Chile, France, Germany, Greece, Israel, Japan, Russian Federation, Spain, Sweden
-
National Cancer Institute (NCI)Canadian Cancer Trials GroupActive, not recruitingAtezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder CancerRecurrent Bladder Urothelial Carcinoma | Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage I Bladder Urothelial Carcinoma AJCC v6 and v7United States, Canada